Tango Therapeutics Management
Management criteria checks 2/4
Tango Therapeutics' CEO is Barbara Weber, appointed in Mar 2017, has a tenure of 7.75 years. total yearly compensation is $3.39M, comprised of 18.5% salary and 81.5% bonuses, including company stock and options. directly owns 1.3% of the company’s shares, worth $4.33M. The average tenure of the management team and the board of directors is 1.2 years and 3.9 years respectively.
Key information
Barbara Weber
Chief executive officer
US$3.4m
Total compensation
| CEO salary percentage | 18.5% |
| CEO tenure | 7.8yrs |
| CEO ownership | 1.3% |
| Management average tenure | 1.2yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth?
Dec 05
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Oct 31Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data
Sep 10What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You
Sep 01Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%
Jun 29Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why
May 30Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%
Mar 19Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans
Mar 06Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk
Jan 08Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)
Aug 12Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?
May 10Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer
Oct 20Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth
Oct 05Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 13Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M
Aug 10We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn
May 28We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow
Jan 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$123m |
| Jun 30 2024 | n/a | n/a | -US$116m |
| Mar 31 2024 | n/a | n/a | -US$112m |
| Dec 31 2023 | US$3m | US$626k | -US$102m |
| Sep 30 2023 | n/a | n/a | -US$100m |
| Jun 30 2023 | n/a | n/a | -US$107m |
| Mar 31 2023 | n/a | n/a | -US$111m |
| Dec 31 2022 | US$5m | US$575k | -US$108m |
| Sep 30 2022 | n/a | n/a | -US$101m |
| Jun 30 2022 | n/a | n/a | -US$92m |
| Mar 31 2022 | n/a | n/a | -US$71m |
| Dec 31 2021 | US$12m | US$514k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$45m |
| Jun 30 2021 | n/a | n/a | -US$52m |
| Mar 31 2021 | n/a | n/a | -US$56m |
| Dec 31 2020 | US$958k | US$492k | -US$52m |
Compensation vs Market: Barbara's total compensation ($USD3.39M) is above average for companies of similar size in the US market ($USD2.22M).
Compensation vs Earnings: Barbara's compensation has been consistent with company performance over the past year.
CEO
Barbara Weber (67 yo)
7.8yrs
Tenure
US$3,391,058
Compensation
Dr. Barbara L. Weber, M.D., has been the President, Director and Chief Executive Officer of Tango Therapeutics Inc., since March 2017 and also served as Chairperson. Dr. Weber serves as a Director of OPY A...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.8yrs | US$3.39m | 1.3% $ 4.3m | |
| President of Research & Development | 1.8yrs | US$3.11m | 0.025% $ 83.9k | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Head of Technical Operations | less than a year | no data | no data | |
| Chief Scientific Officer | 1.2yrs | no data | no data | |
| Chief Legal Officer | 3.3yrs | no data | 0.041% $ 136.3k | |
| Chief Human Resources Officer | less than a year | no data | no data |
1.2yrs
Average Tenure
54.5yo
Average Age
Experienced Management: TNGX's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.8yrs | US$3.39m | 1.3% $ 4.3m | |
| Founder & Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
| Founder & Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
| Founder & Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
| Independent Chairman | 7.9yrs | US$171.53k | 0.0046% $ 15.5k | |
| Independent Director | 3.8yrs | US$141.53k | 0.023% $ 77.5k | |
| Independent Director | 1.1yrs | no data | no data | |
| Independent Director | 3.8yrs | US$148.03k | no data | |
| Independent Director | 6.3yrs | US$139.03k | 0.0046% $ 15.5k | |
| Independent Director | 1.3yrs | US$375.87k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.9yrs | no data | no data |
3.9yrs
Average Tenure
62.5yo
Average Age
Experienced Board: TNGX's board of directors are considered experienced (3.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 21:16 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tango Therapeutics, Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Yuan Zhi | B. Riley Securities, Inc. |
| Eric Schmidt | Cantor Fitzgerald & Co. |